Terremoto Biosciences, Inc.
Last verified 2026-05-08. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $41.0Mattributed |
|---|---|
| Latest round | Funding round, $41.0M, 2026-04-10attributed |
| Founded | 2022 |
| Headquarters | SOUTH SAN FRANCISCO, CA |
| Industry | biotechnology |
| Stage | unknown |
| Website | terremotobiosciences.org |
Terremoto Biosciences is a covalent drug-discovery company creating selective small molecules that covalently bind lysine, found in nearly every protein. It targets oncology and rare disease, including undruggable targets, with a lead AKT1 inhibitor in the clinic. Its edge is lysine-based covalency beyond the cysteine residues older drugs use.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2026-04-10 | Funding round | $41.0M | undisclosed |
Provenance
| Fact | Status | Basis |
|---|---|---|
| Funding round, $41.0M | attributed | sec-edgar named as publisher. No document URL on file. |
| Total raised $41.0M | attributed | sec-edgar named as publisher. No document URL on file. |
| Company existence | self-reported | terremotobiosciences.org, read 2026-05-08 |
| Description | self-reported | terremotobiosciences.org, read 2026-05-08 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
| Date | Fact | Change | Basis |
|---|---|---|---|
| 2026-09-25Latest round: seed, $41.0M, 2026-04-10 → Funding round, $41.0M, 2026-04-10, sec-edgar, No document URL on file | Latest round | seed, $41.0M, 2026-04-10 → Funding round, $41.0M, 2026-04-10 | sec-edgar, No document URL on file |
Records begin 2026-09-24. All changes